News & Updates

UltraVIOLET: Oteseconazole turns in satisfactory results for recurrent yeast infection
UltraVIOLET: Oteseconazole turns in satisfactory results for recurrent yeast infection
26 Jul 2022 byJairia Dela Cruz

In the treatment and prevention of recurrent yeast infection or vulvovaginal candidiasis, oteseconazole performs similarly to standard-of-care fluconazole but better as compared with placebo, as shown in the results of the phase III ultraviolet study.

UltraVIOLET: Oteseconazole turns in satisfactory results for recurrent yeast infection
26 Jul 2022
20-µg hep B vaccine can prevent vertical transmission
20-µg hep B vaccine can prevent vertical transmission
23 Jul 2022
Pre-eclampsia ups risk of nonsyndromic orofacial clefts
Pre-eclampsia ups risk of nonsyndromic orofacial clefts
21 Jul 2022

Only pre-eclampsia, among other hypertensive disorders of pregnancy, contributes to a higher risk of nonsyndromic orofacial clefts (NSOFCs) and its subtypes, a study has found.

Pre-eclampsia ups risk of nonsyndromic orofacial clefts
21 Jul 2022
Women hospitalized with COVID-19 suffer from menstrual changes, worse mental health
Women hospitalized with COVID-19 suffer from menstrual changes, worse mental health
21 Jul 2022

COVID-19 appears to alter the menstrual cycle and impair mental health in women hospitalized for the disease, a recent study has found.

Women hospitalized with COVID-19 suffer from menstrual changes, worse mental health
21 Jul 2022
Pembrolizumab looks good for treated, advanced MSI-H/dMMR endometrial cancer
Pembrolizumab looks good for treated, advanced MSI-H/dMMR endometrial cancer
18 Jul 2022

Use of pembrolizumab helps maintain or improve health-related quality of life in patients with previously treated, advanced endometrial cancer characterized by high levels of microsatellite instability (MSI) or deficient mismatch repair (MSI-H/dMMR), according to data from the phase II KEYNOTE-158 study.

Pembrolizumab looks good for treated, advanced MSI-H/dMMR endometrial cancer
18 Jul 2022